Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab in poorly controlled asthma with eosinophilic airway inflammation
NCT00587288Phase 2Completed
- Sponsor
- Ception Therapeutics
- Start
- Apr 2008
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of reslizumab in asthma, sponsored by Ception Therapeutics. Started Apr 2008; status: completed.
02
Drugs
reslizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00587288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00587288.